Systemic sclerosis is a complex and poorly understood connective tissue disease characterized
by diffuse fibrosis in several organs, especially the skin (
Asano, 2017
;
Bhattacharyya et al., 2012
;
Denton et al., 2006
). IL-33 is found to regulate tissue fibrosis in multiple organs (
Kotsiou et al., 2018
;
Xu et al., 2016
). However, the exact role of IL-33 in fibrosis remains controversial (
Kotsiou et al., 2018
). Previous studies have shown a profibrotic role for the IL-33 cytokine through its
receptor, IL-1 receptor-like 1 (or ST2), which regulates the secretion of the profibrotic
cytokine, IL-13, from eosinophils, M2 macrophages, and type 2 innate lymphoid cells
(
Li et al., 2014
;
Rankin et al., 2010
;
Wu et al., 2018
). However, IL-33 can also play an antifibrotic role through the induction of type
2 innate lymphoid cells and regulatory T cells in several organs, including the skin
(
Cheon et al., 2022
;
Garbern et al., 2019
;
Riedel et al., 2017
). Thus, it is critical to determine the full spectrum of the IL-33 effect in fibrosis
to develop optimal therapies for its use in the treatment of systemic sclerosis and
other fibrosis-associated diseases.Abbreviations:
BLM (bleomycin), IL-33KO (IL-33 knockout), WT (wild-type)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Investigative DermatologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Recent advances in the treatment of skin involvement in systemic sclerosis.Inflamm Regen. 2017; 37: 12
- Fibrosis in systemic sclerosis: common and unique pathobiology.Fibrogenesis Tissue Repair. 2012; 5: S18
- IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo.Proc Natl Acad Sci USA. 2007; 104: 282-287
- Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family.Immunol Rev. 2018; 281: 154-168
- IL-33/regulatory T-cell axis suppresses skin fibrosis.J Invest Dermatol. 2022; 142: 2668-2676.e4
- Mechanisms and consequences of fibrosis in systemic sclerosis.Nat Clin Pract Rheumatol. 2006; 2: 134-144
- Dysregulation of IL-33/ST2 signaling and myocardial periarteriolar fibrosis.J Mol Cell Cardiol. 2019; 128: 179-186
- Nuclear IL-33 restrains the early conversion of fibroblasts to an extracellular matrix-secreting phenotype.Sci Rep. 2021; 11: 108
- The ST2/IL-33 axis in immune cells during inflammatory diseases.Front Immunol. 2017; 8: 475
- IL-33/ST2 axis in organ fibrosis.Front Immunol. 2018; 9: 2432
- IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice.J Allergy Clin Immunol. 2014; 134: 1422-1432.e11
- Pdgfra marks a cellular lineage with distinct contributions to myofibroblasts in lung maturation and injury response.eLife. 2018; 7e36865
- TGF-β: the master regulator of fibrosis.Nat Rev Nephrol. 2016; 12: 325-338
- The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?.PLoS One. 2008; 3e3331
- Nuclear IL-33/SMAD signaling axis promotes cancer development in chronic inflammation.EMBO J. 2021; 40e106151
- IL-33 induces IL-13-dependent cutaneous fibrosis.J Immunol. 2010; 184: 1526-1535
- IL-33-mediated expansion of type 2 innate lymphoid cells protects from progressive glomerulosclerosis.J Am Soc Nephrol. 2017; 28: 2068-2080
- IL-33 is expressed in epithelia from patients with cystic fibrosis and potentiates neutrophil recruitment.J Allergy Clin Immunol. 2013; 131: 913-916
- PDGF promotes dermal fibroblast activation via a novel mechanism mediated by signaling through MCHR1.Front Immunol. 2021; 12: 745308
- IL-33 can promote the process of pulmonary fibrosis by inducing the imbalance between MMP-9 and TIMP-1.Inflammation. 2018; 41: 878-885
- IL-33/ST2 pathway in a bleomycin-induced pulmonary fibrosis model.Mol Med Rep. 2016; 14: 1704-1708
Article info
Publication history
Published online: January 25, 2023
Accepted manuscript published online XXX; corrected proof published online XXXPublication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
